BriaCell Awarded Research Grant from Wiseman Cancer Research Foundation
05 September 2020 - 7:00AM
BriaCell Therapeutics Corp. (“BriaCell” or the “Company”)
(TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology
company specializing in targeted immunotherapy for advanced breast
cancer, is announcing that it has received a research grant from
the Wiseman Cancer Research Foundation, a 501c(3) nonprofit
organization based in Beverly Hills, CA. The research grants are
awarded to individual scientists or entities that pursue
outstanding research in immuno-oncology. Dr. Charles L. Wiseman,
BriaCell’s Scientific Founder and Director, currently serves as
President of the Wiseman Cancer Research Foundation.
“We are grateful for the support that we have
received from the Wiseman Cancer Research Foundation, and are
honored to have received the award,” said Dr. Bill Williams,
BriaCell’s President and CEO.
On a separate note, BriaCell’s Senior Director,
R&D, Markus Lacher, Ph.D., has left BriaCell to pursue other
career interests.
“Markus has done a great job over the past
several years in our R&D division. On behalf of BriaCell team,
I want to thank Markus for his leadership and commitment to
BriaCell, and wish him all the best in his future endeavors,” said
Dr. Williams.
About BriaCell
BriaCell is an immuno-oncology focused
biotechnology company developing targeted and effective approaches
for the management of cancer.
For additional information on BriaCell, please
visit: https://briacell.com/.
Cautionary Note Regarding Forward-Looking
Information
Except for the statements of historical fact,
this news release contains "forward-looking information" within the
meaning of the applicable Canadian securities legislation (also
known as "forward-looking statements") which are subject to known
and unknown risks relevant to the Company in particular and to the
biotechnology and pharmaceutical industries in general,
uncertainties and other factors that may cause actual events to
differ materially from current expectation. These risks are more
fully described in the Company's public filings available at
www.sedar.com.
These forward-looking statements include, but
are not limited to, BriaCell’s plans, objectives, expectations and
intentions. Such forward-looking statements reflect BriaCell's
current beliefs and are based on information currently available to
management. Although the forward-looking statements contained in
this news release are based upon what BriaCell believes are
reasonable assumptions, there can be no assurance that actual
results will be consistent with these forward-looking
statements.
Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. The Company disclaims any
intention or obligation, except to the extent required by law, to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contact Information
For further information, please contact:
BriaCell Therapeutics
Corp.:William V. Williams, MDPresident & CEOPhone:
1-888-485-6340
BriaCell Therapeutics
Corp.:Farrah DeanManager, Corporate DevelopmentEmail:
farrah@BriaCell.com Phone: 1-888-485-6340
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Apr 2024 to May 2024
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From May 2023 to May 2024